Prostate Cancer Market

Market Overview:

The 7 major prostate cancer markets reached a value of USD 13,049.5 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 24,930.6 Million by ​2035​, exhibiting a growth rate (CAGR) of 6.06% during ​2025-2035​.

The prostate cancer market has been comprehensively analyzed in IMARC's new report titled "Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Prostate cancer is a type of cancer that develops in the prostate gland, which is a tiny gland in the male reproductive system that generates fluid for sperm. Prostate cancer in its early stages typically has no symptoms. As cancer advances, it may cause frequent and urgent need to pee, weak urine flow or flow that starts and stops, dysuria, loss of bladder control, fecal incontinence, painful ejaculation, erectile dysfunction, blood in semen, etc. Advanced prostate cancers can spread to adjacent lymph nodes and bones, especially in the pelvis, hips, spine, ribs, head, and neck. Patients suffering from this condition might also experience lethargy, unexplained weight loss, and persistent back or bone pain. Prostate cancer diagnosis typically begins with a digital rectal exam (DRE) and a prostate-specific antigen (PSA) blood test. Healthcare providers might also recommend a prostate biopsy, which removes tissue from the prostate and examines it for cancer cells. Transrectal ultrasound is used to guide this removal, which sends ultrasound waves to the prostate and surrounding tissues through a rectal probe.

The escalating cases of genetic mutations that impair the cell's ability to repair DNA damage, which can result in the accumulation of additional variations and genomic instability, are primarily driving the prostate cancer market. In addition to this, the inflating utilization of immune checkpoint inhibitors, such as pembrolizumab and dostarlimab, to stimulate the body's defense mechanism against cancerous cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of androgen deprivation therapy, since it aims to suppress the production or block the action of male hormones that enhance the proliferation of tumors among patients, is further bolstering the market growth. Apart from this, the rising usage of cancer vaccine that targets a protein called prostate acid phosphatase (PAP) found on prostate cancer cells is acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiosensitizing agents, which helps to make the treatment more potent owing to their numerous benefits, like improved tumor control, reduced toxicity, and synergistic effects with systemic therapies is expected to drive the prostate cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the prostate cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for prostate cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the prostate cancer market in any manner.

Recent Developments:

In November 2024, Curium announced the completion of enrollment in its Phase 3 SOLAR-RECUR research trial. The trial is a multicenter, open-label study designed to assess the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in males with suspected biochemical recurrence of prostate cancer following radical prostatectomy or radiation therapy.

In November 2024, Curium reported that its ECLIPSE trial had reached its primary endpoint. ECLIPSE is a pivotal phase 3 multi-center, open-label, randomized clinical trial that compares the safety and efficacy of 177Lu-PSMA-I&T to hormone therapy in patients with metastatic castration-resistant prostate cancer.

In April 2024, Astellas Pharma declared that the European Commission (EC) approved an extension of labeling for Xtandi (enzalutamide) as single-agent therapy or in combination with androgen deprivation therapy for the therapeutic management of adult men suffering from high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are not eligible for salvage radiotherapy.

Drugs:

Taxotere (Docetaxel) is a taxoid antineoplastic agent that works against prostate cancer by stabilizing microtubules, inhibiting disintegration, and causing apoptosis. It accomplishes this by attaching to beta-tubulin, a component of microtubules required for cell division and other cellular activities. Docetaxel interrupts cell division by blocking microtubule disintegration, which eventually leads to cell death, notably during the G2/M phase of the cell cycle.

Jevtana (Cabazitaxel) is an antineoplastic drug that is used in combination with corticosteroids to treat metastatic castration-resistant prostate cancer in individuals who have previously had docetaxel treatment. Cabazitaxel binds to the N-terminal amino acids of the beta-tubulin subunit, promoting microtubule polymerization while blocking disassembly. This results in microtubule stability, which prevents microtubule cell division. Cabazitaxel ultimately inhibits mitotic and interphase cellular processes and tumor progression.

Xtandi (Enzalutamide) is a second-generation androgen receptor (AR) inhibitor that is used to treat both castration-resistant and metastatic castration-sensitive prostate cancer. Enzalutamide inhibits the androgen signaling pathway threefold while exhibiting no significant AR agonist action. It inhibits androgen binding to its receptor, nuclear translocation of the androgen receptor, and subsequent contact with chromosomal DNA, all of which upregulate oncogenes. Enzalutamide binds to the AR with 5 to 8-fold stronger affinity than first-generation antiandrogens and only 2-3 times reduced affinity than the natural ligand dihydrotestosterone.

Cu 64 PSMA I&T works by targeting prostate-specific membrane antigen (PSMA), a protein overexpressed on prostate cancer cells. The I&T stands for both imaging and potential therapy. The PSMA-targeting ligand in the compound binds to PSMA, guiding the Cu64 isotope, which emits positrons detectable by PET imaging, to the cancer cells. This allows for visualizing the cancer's location, size, and spread, aiding in diagnosis and treatment planning. Cu64's radioactive characteristics make it a desirable candidate for targeted radiotherapy.

177Lu-PSMA-I&T, a radioligand therapy from Curium Pharma, targets prostate cancer cells expressing the prostate-specific membrane antigen. The mechanism involves PSMA-I&T binding to PSMA on the surface of cancer cells, which causes the associated 177Lutetium (177Lu) isotope to produce beta particles. These particles disrupt the DNA within cancer cells, causing cell death.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the prostate cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the prostate cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current prostate cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the prostate cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the prostate cancer market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the prostate cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of prostate cancer across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of prostate cancer by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of prostate cancer by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with prostate cancer across the seven major markets?
• What is the size of the prostate cancer patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of prostate cancer?
• What will be the growth rate of patients across the seven major markets?

Prostate Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for prostate cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the prostate cancer market?
• What are the key regulatory events related to the prostate cancer market?
• What is the structure of clinical trial landscape by status related to the prostate cancer market?
• What is the structure of clinical trial landscape by phase related to the prostate cancer market?
• What is the structure of clinical trial landscape by route of administration related to the prostate cancer market?